ALLR NASDAQ
Tarpon Springs, FL 34689
US
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Jensen Thomas | A-Award | 200,000 | — | 2026-01-28 |
| McLaughlin Gerald W. | A-Award | 45,000 | — | 2026-01-28 |
| Graff Jeremy R. | A-Award | 133,333 | — | 2026-01-28 |
| Ervin Jeffrey S | A-Award | 150,000 | — | 2026-01-28 |
| Hoeiland Jesper | A-Award | 25,000 | — | 2026-01-07 |